Literature DB >> 6870234

Naloxone attenuates self-abusive behavior in developmentally disabled clients.

C A Sandman, P C Datta, J Barron, F K Hoehler, C Williams, J M Swanson.   

Abstract

The opiate antagonist naloxone was effective in reducing self-abusive behavior in two mentally retarded clients with an extensive history of such behavior. Three doses of naloxone (0.1, 0.2, 0.4 mg) were compared with a vehicle solution in a double-blind, crossover design. Naloxone greatly attenuated self-abusive episodes in one client and eliminated them entirely in the second client. In addition, use of self-restraining behavior by one client was reduced. The findings suggested that some clients with self-injurious behavior may have disturbances of the endogenous opiate system. Maintenance of self-abuse by tonically elevated pain threshold and/or by the putative addictive characteristics of such behavior was discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6870234     DOI: 10.1016/s0270-3092(83)80014-9

Source DB:  PubMed          Journal:  Appl Res Ment Retard        ISSN: 0270-3092


  10 in total

1.  Initial aggravation of self-injurious behavior in autistic patients receiving naltrexone treatment.

Authors:  R Knabe; P Schulz; J Richard
Journal:  J Autism Dev Disord       Date:  1990-12

2.  Brief report: plasma beta-endorphin and cortisol levels in autistic patients.

Authors:  C A Sandman; J L Barron; A Chicz-DeMet; E M DeMet
Journal:  J Autism Dev Disord       Date:  1991-03

3.  Brief report: a synopsis of an open-trial of naltrexone treatment of autism with four children.

Authors:  J Panksepp; P Lensing
Journal:  J Autism Dev Disord       Date:  1991-06

Review 4.  Multidisciplinary assessment and treatment of self-injurious behavior in autism spectrum disorder and intellectual disability: integration of psychological and biological theory and approach.

Authors:  Noha F Minshawi; Sarah Hurwitz; Danielle Morriss; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2015-06

5.  Brain opioids and autism: an updated analysis of possible linkages.

Authors:  T L Sahley; J Panksepp
Journal:  J Autism Dev Disord       Date:  1987-06

6.  A case report of naltrexone treatment of self-injury and social withdrawal in autism.

Authors:  A S Walters; R P Barrett; C Feinstein; A Mercurio; W T Hole
Journal:  J Autism Dev Disord       Date:  1990-06

7.  Naltrexone treatment reverses astrocyte atrophy and immune dysfunction in self-harming macaques.

Authors:  Kim M Lee; Kevin B Chiu; Peter J Didier; Kate C Baker; Andrew G MacLean
Journal:  Brain Behav Immun       Date:  2015-07-17       Impact factor: 7.217

Review 8.  Pharmacological treatment of self-injurious behavior in mentally retarded persons.

Authors:  N N Singh; C J Millichamp
Journal:  J Autism Dev Disord       Date:  1985-09

9.  Non-suicidal self-injurious behavior, endogenous opioids and monoamine neurotransmitters.

Authors:  Barbara Stanley; Leo Sher; Scott Wilson; Rolf Ekman; Yung-yu Huang; J John Mann
Journal:  J Affect Disord       Date:  2009-11-25       Impact factor: 4.839

10.  Pain reactivity and plasma beta-endorphin in children and adolescents with autistic disorder.

Authors:  Sylvie Tordjman; George M Anderson; Michel Botbol; Sylvie Brailly-Tabard; Fernando Perez-Diaz; Rozenn Graignic; Michèle Carlier; Gérard Schmit; Anne-Catherine Rolland; Olivier Bonnot; Séverine Trabado; Pierre Roubertoux; Guillaume Bronsard
Journal:  PLoS One       Date:  2009-08-26       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.